Leading Patent-Cliff Exposure & CMS Drug Spending Portfolio

Leading (US): 5 reconciled FDA prescription therapies, $23.7M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies5
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$23.7M
2024 Medicare Part D Spend$19.5M
2024 Medicaid Spend$4.2M
California HCAI SB 17 Filings1 WAC filings (max 42.7% 2-yr change)